( c o n t r o l group). A l l t h e parameters s t u d i e d were s t a b l e i n t h e c o n t r o l group. With both doses, DTZ decreased mean a r t e r i a l blood p r e s s u r e (28 and 24%, p < 0.001) and h e a r t r a t e ( 9 and 13%), p < 0.001). Cardiac index and systemic v a s c u l a r r e s i s t a n c e were n o t modified. DTZ markedly i n c r e a s e d t h e coronary blood flow (54% and 55% a f t e r 0.5 and 1 mg/kg r e s p e c t i v e l y , p < 0.01) w i t h no change i n t h e endocardium/epicardium r a t i o . Coronary r e s i s t a n c e was decreased. To a l e s s e r e x t e n t , DTZ (0.5 mg/kg) i n c r e a s e d s i g n i f i c a n t l y (p < 0.05) t h e blood flow t o t h e b r a i n (27%), l i v e r ( 7 % ) , ileum ( 6 % ) and diaphragm (26%). I n c o n t r a s t , DTZ a t a dose of 1 mg/kg induced a s i g n i f i c a n t d e c r e a s e i n r e n a l blood flow (37%, p < 0.05). W e conclude t h a t i n t h e newborn p i g l e t , blockade of t h e slow calcium channels by DTZ induces a coronary v a s o d i l a t a t i o n . The d e c r e a s e i n r e n a l blood flow a f t e r high doses r e q u i r e s f u r t h e r i n v e s t i g a t i o n .
France.
Calcium a n t a g o n i s t s a r e a new c l a s s of drugs which may be u s e f u l during t h e n e o n a t a l p e r i o d . Since t h e i r e f f e c t s on r e g i o n a l blood flows (RBF) had n o t been s t u d i e d , we a s s e s s e d t h e e f f e c t s of IV d i l t i a z e m (DTZ) on hemodynamics and RBF measured w i t h r a d i o a c t i v e microspheres i n urethan-a n e s t h e t i z e d p i g l e t s (age = 5.4 + 0.6 d ) . S i x p i g l e t s received DTZ ( 0 . 5 and 1 mg/kg, l e a d i n g t o p l a s m a c o n c e n t r a t i o n s of 0.52 + 0.03 and 1.14 2 0.07 ug/ml r e s p e c t i v e l y , a s measured by h i g x p r e s s u r e l i q u i d chromatography).
S i x o t h e r p i g l e t s received s a l i n e ( c o n t r o l group). A l l t h e parameters s t u d i e d were s t a b l e i n t h e c o n t r o l group. With both doses, DTZ decreased mean a r t e r i a l blood p r e s s u r e (28 and 24%, p < 0.001) and h e a r t r a t e ( 9 and 13%), p < 0.001). Cardiac index and systemic v a s c u l a r r e s i s t a n c e were n o t modified. DTZ markedly i n c r e a s e d t h e coronary blood flow (54% and 55% a f t e r 0.5 and 1 mg/kg r e s p e c t i v e l y , p < 0.01) w i t h no change i n t h e endocardium/epicardium r a t i o . Coronary r e s i s t a n c e was decreased. To a l e s s e r e x t e n t , DTZ (0.5 mg/kg) i n c r e a s e d s i g n i f i c a n t l y (p < 0.05) t h e blood flow t o t h e b r a i n (27%), l i v e r ( 7 % ) , ileum ( 6 % ) and diaphragm (26%). I n c o n t r a s t , DTZ a t a dose of 1 mg/kg induced a s i g n i f i c a n t d e c r e a s e i n r e n a l blood flow (37%, p < 0.05). W e conclude t h a t i n t h e newborn p i g l e t , blockade of t h e slow calcium channels by DTZ induces a coronary v a s o d i l a t a t i o n . The d e c r e a s e i n r e n a l blood flow a f t e r high doses r e q u i r e s f u r t h e r i n v e s t i g a t i o n .
SERUM NETILMICIN LEVELS IN PREMATURE 1NFANTS.Leandro
Cordero, L a r r Arwood, Susan OiCenzo, James Visconti. r m a t i o n and t h e unique physiol o g y of prematures d u r i n g t h e f i r s t week o f l i f e makes i n t e r p r et a t i o n o f peak and trough l e v e l s more d i f f i c u l t . T h i s study was designed t o measure serum n e t i l m i c i n l e v e l s f o l l o w i n g a 2.5 mg/kg push I V i n f u s i o n . Blood samples were taken on t h e f i f t h day o f therapy (age) one hour b e f o r e and one, s i x and eleven hours f o l l o w i n g a dose. F i f t e e n prematures weighing 1000-1500 gms a t b i r t h and 20 others whose weight ranged from 1501-2750 gms comp r i s e d t h e study population. A l l prematures were AGA and o f them, o n l y 2 were severely asphyxiated. A t t h e time o f t h e study, 10 neonates were s t i l l on r e s p i r a t o r s . Serum and u r i n e sodium and c r e a t i n i n e s , BUN and u r i n a l y s i s were obtained i n 28 o f these i n f a n t s . No evidence o f renal d y s f u n c t i o n was found. A l l i nf a n t s received 100 mg/kg I V a m p i c i l l i n every 12 hours b u t none were being t r e a t e d w i t h d i u r e t i c s . Serum n e t i l m i c i n l e v e l s were measured by an enzymatic immunoassay (SYVA), peak and trough were c a l c u l a t e d by e x t r a p o l a t i n g t h e f i r s t o r d e r decay curve. Peak l e v e l s ranged from 3.4 t o 14.4 mcglml ( ? 6.6 i-2.5mcglml SD) and 80% o f them were above 4 mcglml. H a l f o f t h e small premat u r e s (1000-1500 gm Bwgt) presented trough values above 3mcglml. Pharmacokinetic a n a l y s i s o f our data p r e d i c t s t h a t a 2.5 mglkg l o a d i n g dose f o l l o w e d by 2 mg/kg given every 12 hours w i l l decrease by one-half t h e number o f small prematures exceeding t h e considered "safe" trough l e v e l ( 5 3 mcgjml).
TOLAZOLINE INHIBITION OF PLATELET AGGREGATION.
357 James T. Courtney, Kathy A. Kenal, and Joseph A.
Garcia-Prats, (Spon. by Thomas N. Hansen), Baylor College of Medicine, Department of P e d i a t r i c s , Houston, Tx.
T o l a z o l i n e (TZ), a n imidazoline compound w i t h v a s o d i l a t o r y and h i s t a m i n i c p r o p e r t i e s , i s used i n t h e therapy of n e o n a t a l p e r s i s t e n t pulmonary h y p e r t e n s i o n (PPH).
I n h i b i t i o n of thromboxane A2 (TBX-A) s y n t h e s i s by TZ has been reported. The inv i t r o e f f e c t s of TZ on p l a t e l e t a g g r e g a t i o n were s t u d i e d . P l a t e l e t r i c h plasma obtained from 6 h e a l t h y a d u l t s and from cord blood samples of 6 h e a l t h y t e r n i n f a n t s was incubated w i t h TZ and aggregated w i t h ADP ( l o p ) . At i n c r e a s i n g c o n c e n t r a t i o n s of TZ, d e c r e a s e s i n maximal a g g r e g a t i o n occurred, followed by d i s a g g r e g a t i o n (meanfSEM) :
The r e l a t i o n s h i p between TZ c o n c e n t r a t i o n and both maximal and lo-minute a g g r e g a t i o n was l i n e a r up t o l o 3 )~g / m l (r20.88). The i n h i b i t i o n of primary a g g r e g a t i o n a t t h e h i g h e s t TZ concent rat i o n s i s i n c o n s i s t e n t with TBX-A i n h i b i t i o n alone. Preliminary d a t a , using a radioimmunoassay, suggest a n i n c r e a s e i n p l a t e l e t c y c l i c AMP when incubated w i t h TZ, perhaps mediated by h i s tamine receptors.
In-vivo i n h i b i t i o n of p l a t e l e t a g g r e g a t i o n and TRX-A r e l e a s e by TZ may be b e n e f i c a l i n some f o r n s of PPH. 
v i o u s l y shown t h a t A4AP has t h e same a c t i v i t y a s a c e t y l s a l i c y l i c a c i d (ASA) i n producing c o n s t r i c t i o n of t h e duct u s a r t e r i o s u s (DA) i n t h e c h r o n i c a l l y c a t h e t e r i z e d sheep f e t u s .
W e r e p o r t here t h a t PG12 s y n t h e s i s by f e t a l lamb D A homogenates i s i n h i b i t e d by A4AP c o n c e n t r a t i o n s s i m i l a r t o l e v e l s achieved i n the f e t u s . The K I was lower than t h a t obtained f o r b r a i n homogenates ( T a b l e ) . Analogues of A4AP synthesized i n t h i s laborat o r y : N-Acetyl-3-AminoPhenol (A3AP) and N-Acetyl-2-AminoPhenol (AZAP), d i f f e r from A4AP i n t h a t A3AP cannot he oxidized whereas A4AP and A2AP o x i d i z e r e a d i l y t o r e a c t i v e i n t e r m e d i a t e s . A4AP and A2AP were a s e f f e c t i v e a s ASA t o i n h i b i t PG12 s y n t h e s i s i n t h e D A whereas A3AP was 25 t o 50 times l e s s e f f e c t i v e . The a b i l i t y of p r o s t a g l a n d 359 G g i o v a n n i ) . Univ. of Pa. Sch. of Med., Pennsylvania -t s i g n i f i c a n t decrease from c o n t r o l (p<.01)
i n s y n t h e t a s e t o o x i d i z e A4AP has been demo n s t r a t e d . W e conclude from t h e s e s t u d i e s t h a t t h e mechanism whereby A4AP i s an i n h i b i t o r of p r o s t a g l a n d i n s y n t h e s i s i s v i a a metabolic o x i d a t i o n s i m i l a r t o t h a t which can lead t o h e p a t i c
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H o s p i t a l , S e c t i o n on Newborn P e d i a t r i c s . P h i l a d e l~h i a .
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The occurrence of apnea i n term and n e a r term n e o n a t e s i s usua l l y a s s o c i a t e d with a d e f i n i t i v e o r g a n i c e t i o l o g y . We haye r e c e n t l y s t u d i e d 4 i n f a n t s (x GA=37 wks, range 35-40 wks; x BW= 2660g, range 1980-31408) with s i g n i f i c a n t apnea and i n c r e a s e d p e r i o d i c b r e a t h i n g . A l l i n f a n t s had been born by c e s a r e a n sect i o n (apgars 819) f o l l o w i n g uncomplicated p e r i n a t a l c o u r s e s and were w e l l u n t i l 4-6 days of age when apnea developed. A l l mothers had been b r e a s t f e e d i n g and r e c e i v i n g codeine 60 mg every 4-6 hours f o r a n a l g e s i a .
B r e a s t f e e d i n g was h e l d f o r 24 h o u r s and t h e codeine d i s c o n t i n u e d . Codeine was n o t d e t e c t e d i n t h e serum of one i n f a n t . Apnea r e s o l v e d w i t h i n 24-48 hours and t h e i n f a n t s were discharged. Repeat cardiorespirograms withi n 7-10 days were normal. Experience i n t h e s e 4 i n f a n t s suggest: 1)Although only t r a c e amounts of codeine a r e r e p o r t e d t o e n t e r b r e a s t milk, i t may b e s u f f i c i e n t t o a f f e c t newborn r e s p i r a t o r y c o n t r o l . 2)The metabolism of codeine i n t h e newborn i s uncert a i n . It may t a k e 4-5 days f o r s u f f i c i e n t drug t o accumulate and i n f l u e n c e r e s p i r a t o r y c o n t r o l .
3)Caution should be used with codeine a d m i n i s t r a t i o n i n b r e a s t f e e d i n g mothers. l r d i a c and systemic p r e s s o r e f f e c t s of PGD? a r e v a r i a b l e i n previous r e p o r t s -u t i l i z i & g animals p r e t r e a t e d Gith p e n t o b a r b i t a l p a r a l y s i s and indomethacin. To t e s t PGD2 e f f e c t s without o t h e r d r u g s , 16 lambs were operated a t <24 hours t o l i g a t e t h e ductus a r t e r i o s i s and t o place c a t h e t e r s i n t h e a o r t a , pulmonary a r t e r y (PA), l e f t atrium (LA) and i n f e r i o r vena cava (IVC) and a flow t r a n s d u c e r around t h e main PA. Vascular and c a r d i a c e f f e c t s of PGD2 a t 0.1, 1 , and 10 ug/kg x 1 min on a o r t i c (SAP), PA and LA p r e s s u r e (PAP, LAP), c a r d i a c output ( c o ) , h e a r t r a t e (HR) and systemic and pulmonary v a s c u l a r r e s i s t a n c e (SVR, PVR) were s t u d i e d during normoxia ( N ) and hypoxia (H) a t ages 2.5, 11.4 and 25.5 days. PGD2 had age and oxygen r e l a t e d pulmonary vasodepressor e f f e c t s . SAP and SVR increased from 5 t o 20 mmHg (p<.05-.0001) a t a l l doses and ages under both N and H. H R and c a r d i a c output f e l l a t a l l doses. A; 10 uglkglmin:
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-----, PGD2 i n i n t a c t unanesthetized lambs i s a moderate systemic p r e s s o r and depresses c a r d i a c f u n c t i o n , perhaps r e f l e x l y . N e i t h e r age nor hypoxemia a l t e r s t h e response, u n l i k e pulmonary v a s c u l a r changes. Thus, i n t e r a c t i o n s of PGD2 with o t h e r drugs a l t e r c a r d i a c and systemic c i r c u l a t o r y r e s o n s e s . I11 i n f a n t s t r e a t e d with combinations of b a r b i t u r a t e s , indomethacin and/or p a r a l y t i c agents may e x h i b i t q u i t e v a r i a b l e responses i f a l s o t r e a t e d with PGD2.
